Compile Data Set for Download or QSAR
Report error Found 4052 with Last Name = 'xu' and Initial = 'r'
TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282564(US9884843, Compound 1 | (R)-3-((4-bromo-2,2-difluo...)
Affinity DataEC50:  64nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282572((R)-3-((4-(difluoromethyl)-2,2-difluoro-3-hydroxy-...)
Affinity DataEC50:  62nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282578(US9884843, Compound 7)
Affinity DataEC50:  330nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282581(US9884843, Compound 9 | 4-Bromo-5-(3-chloro-5-fluo...)
Affinity DataEC50:  65nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282584(US9884843, Compound 11 | 4-Chloro-5-(3-chloro-5-fl...)
Affinity DataEC50:  125nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282598(US9884843, Compound 14 | 5-(3-Chloro-5-fluoropheno...)
Affinity DataEC50:  89nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282632(US9884843, Compound 25 | 5-(3-Chloro-5-fluoropheno...)
Affinity DataEC50:  29nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282634(US9884843, Compound 19 | 3-Amino-4-(difluoromethyl...)
Affinity DataEC50:  87nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282656(US9884843, Compound 22 | 4-(Difluoromethyl)-5-(3,5...)
Affinity DataEC50:  9nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282682(US9884843, Compound 26 | 3-((3-Amino-4-(difluorome...)
Affinity DataEC50:  200nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282685(US9884843, Compound 40 | 3-((4-(Difluoromethyl)-2,...)
Affinity DataEC50:  14nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282697(US9884843, Compound 41 | (R)-3-((3-Amino-4-(difluo...)
Affinity DataEC50:  680nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282572((R)-3-((4-(difluoromethyl)-2,2-difluoro-3-hydroxy-...)
Affinity DataEC50:  9nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282708(4-(Difluoromethyl)-5-(3,5-difluorophenoxy)-2,2- di...)
Affinity DataEC50:  90nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282708(4-(Difluoromethyl)-5-(3,5-difluorophenoxy)-2,2- di...)
Affinity DataEC50:  67nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282713(US9884843, Compound 57 | (R)-4-Bromo-5-(3-chloro-5...)
Affinity DataEC50:  45nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282731(US9884843, Compound 75 | (R)-4-bromo-5-((5-chlorop...)
Affinity DataEC50:  178nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282734(US9884843, Compound 78 | (R)-5-((4-Bromo-2,2-diflu...)
Affinity DataEC50:  330nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282741(US9884843, Compound 85 | (R)-3-((4-chloro-2,2-difl...)
Affinity DataEC50:  77nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282756(US9884843, Compound 100 | 5-(3,5-Difluorophenoxy)-...)
Affinity DataEC50:  18nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282761(US9884843, Compound 105 | 5-(3-cyano-5-fluoro-phen...)
Affinity DataEC50:  48nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM282775(US9884843, Compound 119)
Affinity DataEC50:  31nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/5/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372960(US9896418, Compound 1 | US10597366, Compound 1)
Affinity DataEC50:  250nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372961(US9896418, Compound 2 | US10597366, Compound 2)
Affinity DataEC50:  62nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372964(US9896418, Compound 8 | US10597366, Compound 8)
Affinity DataEC50:  33nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372966(US9896418, Compound 9 | US10597366, Compound 9)
Affinity DataEC50:  6nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372972(US9896418, Compound 11 | US10597366, Compound 11)
Affinity DataEC50:  15nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372976(US9896418, Compound 15 | US10597366, Compound 15)
Affinity DataEC50:  13nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372979(US9896418, Compound 17 | US10597366, Compound 17)
Affinity DataEC50:  160nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372986(US9896418, Compound 25 | US10597366, Compound 25)
Affinity DataEC50:  37nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372987(US9896418, Compound 34 | US10597366, Compound 34)
Affinity DataEC50:  460nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372988(US9896418, Compound 41 | US10597366, Compound 41)
Affinity DataEC50:  570nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372989(US9896418, Compound 55 | US10597366, Compound 55)
Affinity DataEC50:  35nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372990(US9896418, Compound 60 | US10597366, Compound 60)
Affinity DataEC50:  40nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372991(US9896418, Compound 63 | US10597366, Compound 63)
Affinity DataEC50:  20nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372992(US9896418, Compound 64 | US10597366, Compound 64)
Affinity DataEC50:  1nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372993(US9896418, Compound 67)
Affinity DataEC50:  220nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372994(US9896418, Compound 74 | US10597366, Compound 74)
Affinity DataEC50:  320nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372995(US9896418, Compound 78 | US10597366, Compound 78)
Affinity DataEC50:  750nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372996(US9896418, Compound 80 | US10597366, Compound 80)
Affinity DataEC50:  630nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372997(US9896418, Compound 98 | US10597366, Compound 98)
Affinity DataEC50:  1.58E+3nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372998(US9896418, Compound 99 | US10597366, Compound 99)
Affinity DataEC50:  550nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372999(US9896418, Compound 102 | US10597366, Compound 102)
Affinity DataEC50:  640nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373000(US9896418, Compound 124 | US10597366, Compound 124)
Affinity DataEC50:  400nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373001(US9896418, Compound 132 | US10597366, Compound 132)
Affinity DataEC50:  680nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373002(US9896418, Compound 133 | US10597366, Compound 133)
Affinity DataEC50:  1.87E+3nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373003(US9896418, Compound 155 | US10597366, Compound 155)
Affinity DataEC50:  140nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373004(US9896418, Compound 158 | US10597366, Compound 158)
Affinity DataEC50:  6nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373005(US9896418, Compound 159 | US10597366, Compound 159)
Affinity DataEC50:  7nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM373006(US9896418, Compound 161 | US10597366, Compound 161)
Affinity DataEC50:  11nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 4052 total ) | Next | Last >>
Jump to: